
The Danish investment company NB Capital lead by CEO Florian Schönharting has led a direct attack on the acting board in the Canadian biotech company, QLT, by replacing six out of seven of its members, after NB Capital, which owns about 15 % of the shares, secured support from a number of the other major share holders.
The replacement came about after an intense verbal showdown with the acting board, according to stock market announcements from QLT, just as the takeover has been relayed by several international media channels.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app